Full text is available at the source.
Drugs targeting GLP-1 and combined GIP/GLP-1 receptors for treating obesity in teenagers and older adults
Updated
Abstract
GLP-1 receptor agonists may offer significant benefits in weight reduction for adolescents and the elderly.
- Liraglutide, semaglutide, and tirzepatide are identified as promising treatments for obesity.
- These medications may have varying safety considerations for adolescents and elderly populations.
- The review highlights the importance of including underrepresented groups in clinical trials.
- Clinical studies and real-world data indicate effectiveness in weight management for these demographics.
- Emerging GLP-1 molecules are being explored for potential use in these special populations.
Simplified